Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TransMedics (TMDX) EBIT (2018 - 2025)

TransMedics has reported EBIT over the past 8 years, most recently at $21.3 million for Q4 2025.

  • Quarterly results put EBIT at $21.3 million for Q4 2025, up 146.1% from a year ago — trailing twelve months through Dec 2025 was $108.6 million (up 189.59% YoY), and the annual figure for FY2025 was $108.6 million, up 189.59%.
  • EBIT for Q4 2025 was $21.3 million at TransMedics, down from $23.3 million in the prior quarter.
  • Over the last five years, EBIT for TMDX hit a ceiling of $36.6 million in Q2 2025 and a floor of -$28.3 million in Q3 2023.
  • Median EBIT over the past 5 years was -$1.5 million (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in EBIT: crashed 411.09% in 2023 and later soared 1480.57% in 2024.
  • TransMedics' EBIT stood at -$11.3 million in 2021, then skyrocketed by 40.16% to -$6.8 million in 2022, then skyrocketed by 138.4% to $2.6 million in 2023, then skyrocketed by 232.08% to $8.6 million in 2024, then skyrocketed by 146.1% to $21.3 million in 2025.
  • The last three reported values for EBIT were $21.3 million (Q4 2025), $23.3 million (Q3 2025), and $36.6 million (Q2 2025) per Business Quant data.